Wockhardt Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Wockhardt.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	18.4%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

Nov 02

What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

Aug 20

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Jul 27

Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Jun 30

Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Jun 22

Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

Feb 21

There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

Dec 19

Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Jul 26

Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

May 18

Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Jan 26

What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

Dec 01

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Wockhardt yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NSEI:WOCKPHARMA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2024	29,250	-3,430	N/A	N/A	N/A
3/31/2024	28,300	-4,630	30	2,190	N/A
12/31/2023	27,760	-5,010	N/A	N/A	N/A
9/30/2023	27,740	-5,140	20	1,960	N/A
6/30/2023	27,000	-6,260	N/A	N/A	N/A
3/31/2023	26,570	-5,590	-560	1,530	N/A
12/31/2022	26,280	-6,100	N/A	N/A	N/A
9/30/2022	27,820	-5,210	240	2,250	N/A
6/30/2022	29,650	-2,980	N/A	N/A	N/A
3/31/2022	32,300	-2,440	2,010	4,130	N/A
12/31/2021	32,074	-787	N/A	N/A	N/A
9/30/2021	31,175	-567	1,714	2,857	N/A
6/30/2021	29,696	-867	N/A	N/A	N/A
3/31/2021	27,080	-2,990	-3,570	-2,870	N/A
12/31/2020	27,633	-1,780	N/A	N/A	N/A
9/30/2020	24,910	-2,583	-2,486	-896	N/A
6/30/2020	27,167	-3,181	N/A	N/A	N/A
3/31/2020	28,440	-1,638	4,766	6,490	N/A
12/31/2019	35,136	-1,320	N/A	N/A	N/A
9/30/2019	36,903	-2,127	4,785	7,311	N/A
6/30/2019	40,138	-1,533	N/A	N/A	N/A
3/31/2019	35,658	-2,897	-915	1,833	N/A
12/31/2018	41,851	-3,346	N/A	N/A	N/A
9/30/2018	41,445	-3,043	N/A	N/A	N/A
6/30/2018	40,536	-2,848	N/A	N/A	N/A
3/31/2018	39,245	-6,083	N/A	684	N/A
12/31/2017	37,822	-6,285	N/A	N/A	N/A
9/30/2017	37,724	-6,416	N/A	N/A	N/A
6/30/2017	38,148	-6,213	N/A	N/A	N/A
3/31/2017	39,664	-1,957	N/A	-2,695	N/A
12/31/2016	41,695	485	N/A	N/A	N/A
9/30/2016	42,485	1,745	N/A	N/A	N/A
6/30/2016	44,134	2,499	N/A	N/A	N/A
3/31/2016	44,532	2,507	N/A	716	N/A
12/31/2015	46,085	3,168	N/A	N/A	N/A
9/30/2015	49,148	6,031	N/A	N/A	N/A
6/30/2015	45,497	4,992	N/A	N/A	N/A
3/31/2015	44,815	4,049	N/A	3,550	N/A
12/31/2014	43,867	4,452	N/A	N/A	N/A
9/30/2014	42,410	4,024	N/A	N/A	N/A
6/30/2014	44,632	5,374	N/A	N/A	N/A
3/31/2014	48,304	8,407	N/A	14,763	N/A
12/31/2013	52,772	11,010	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if WOCKPHARMA's forecast earnings growth is above the savings rate (6.7%).

Kazançlar ve Piyasa: Insufficient data to determine if WOCKPHARMA's earnings are forecast to grow faster than the Indian market

Yüksek Büyüme Kazançları: Insufficient data to determine if WOCKPHARMA's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if WOCKPHARMA's revenue is forecast to grow faster than the Indian market.

Yüksek Büyüme Geliri: Insufficient data to determine if WOCKPHARMA's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if WOCKPHARMA's Return on Equity is forecast to be high in 3 years time

Wockhardt Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up

Wockhardt's Miqnaf (Nafithromycin) Receives Favourable Recommendation from Subject Expert Committee of Central Drugs Standard Control Organization

Wockhardt's WCK 6777 Receives Fast Track Designation by US FDA, Completes Phase I Study

What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You

First quarter 2025 earnings released: ₹0.95 loss per share (vs ₹9.28 loss in 1Q 2024)

Wockhardt Limited to Report Q1, 2025 Results on Aug 09, 2024

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation

Wockhardt Limited, Annual General Meeting, Jun 28, 2024

Wockhardt Limited Appoints Ahmad Javed as Additional (Independent) Director

Full year 2024 earnings released: ₹32.05 loss per share (vs ₹38.80 loss in FY 2023)

Wockhardt Limited to Report Q4, 2024 Results on May 28, 2024

Wockhardt Limited Announces Cessation of Independent Directors

Wockhardt Limited has completed a Follow-on Equity Offering in the amount of INR 4.800429 billion.

New minor risk - Shareholder dilution

Wockhardt Limited has filed a Follow-on Equity Offering.

Wockhardt Limited has filed a Follow-on Equity Offering.

Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%

Third quarter 2024 earnings released: ₹5.75 loss per share (vs ₹6.62 loss in 3Q 2023)

There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹5.37 loss per share (vs ₹13.15 loss in 2Q 2023)

There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues

Insufficient new directors

Wockhardt Limited to Report Q1, 2024 Results on Aug 14, 2023

Wockhardt Limited, Annual General Meeting, Aug 14, 2023

Wockhardt Limited to Report Q4, 2023 Results on May 26, 2023

Third quarter 2023 earnings released: ₹6.62 loss per share (vs ₹0.61 loss in 3Q 2022)

Wockhardt Limited to Report Q3, 2023 Results on Feb 13, 2023

Insufficient new directors

Second quarter 2023 earnings released: ₹13.15 loss per share (vs ₹3.03 profit in 2Q 2022)

Wockhardt Announces Successful Initiation of Global Phase 3 Clinical Study of Its Novel Antibiotic WCK 5222

Wockhardt Limited to Report Q1, 2023 Results on Aug 12, 2022

Wockhardt Limited, Annual General Meeting, Aug 12, 2022

Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?

Wockhardt Limited Announces Chief Financial Officer Changes

Full year 2022 earnings released

Insufficient new directors

Wockhardt Limited to Report Q4, 2022 Results on May 30, 2022

Wockhardt Limited Announces Chief Financial Officer Changes

Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Wockhardt Gets CDSCO Nod for Exporting Up to 100 Million Doses of Sputnik Vaccines

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt

Second quarter 2022 earnings released: EPS ₹3.03 (vs ₹0.32 in 2Q 2021)

Board Member recently bought ₹4.4m worth of stock

Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being

Company Secretary & Compliance Officer Gajanand Sahu has left the company

Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020)

Insider recently sold ₹20m worth of stock

Full year 2021 earnings released: ₹27.02 loss per share (vs ₹14.79 loss in FY 2020)

Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)

UK Government Announces Covid-19 Vaccination Contract Extension with Wockhardt

Third quarter 2021 earnings released: EPS ₹1.38 (vs ₹0.87 in 3Q 2020)

Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)

Wockhardt Limited to Report Q3, 2021 Results on Jan 29, 2021

New 90-day high: ₹551

Insider recently sold ₹1.6m worth of stock

New 90-day high: ₹487

What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?

New 90-day high: ₹393

First quarter earnings released

Wockhardt Limited to Report Q1, 2021 Results on Aug 29, 2020

New 90-day high - ₹304

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin